APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gefitinib

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Gefitinib Market Analysis and Forecast 2026-2032

23 December 2025208 pages

Choose your research edition.

Industry ResearchGefitinib Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Gefitinib Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Gefitinib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gefitinib Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Gefitinib Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Gefitinib market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Gefitinib is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Gefitinib is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Gefitinib is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Gefitinib is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Gefitinib include Qilu Pharmaceutical, AstraZeneca, Zuventus Healthcare, United Biotech, Sichuan Xieli Pharmaceutical, Panacea Biotec, Nobel Ilac Sanayii Ve Ticaret, Nishchay Pharmaceuticals and Natco Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Gefitinib, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Gefitinib, also provides the sales of main regions and countries. Of the upcoming market potential for Gefitinib, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gefitinib sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Gefitinib market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Gefitinib sales, projected growth trends, production technology, application and end-user industry.

Gefitinib Segment by Company

Qilu Pharmaceutical

AstraZeneca

Zuventus Healthcare

United Biotech

Sichuan Xieli Pharmaceutical

Panacea Biotec

Nobel Ilac Sanayii Ve Ticaret

Nishchay Pharmaceuticals

Natco Pharma

Jodas Expoim

Hetero Drugs

Globela Pharma

Glenmark Pharmaceuticals

Flagship Biotech International

Ethypharm

Dr Reddy's Laboratories

Cipla

Celon Laboratories

Cadila Pharmaceuticals

Accure Labs

Gefitinib Segment by Type

10 Tables/Box

30 Tables/Box

90 Tables/Box

Gefitinib Segment by Application

Drug Center

Hospital

Clinic

Others

Gefitinib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gefitinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gefitinib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gefitinib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Gefitinib in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Gefitinib manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gefitinib sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gefitinib Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 10 Tables/Box Major Manufacturers Table 3. 30 Tables/Box Major Manufacturers Table 4. 90 Tables/Box Major Manufacturers Table 5. Global Gefitinib Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Drug Center Major Manufacturers Table 7. Hospital Major Manufacturers Table 8. Clinic Major Manufacturers Table 9. Others Major Manufacturers Table 10. Gefitinib Industry Trends Table 11. Gefitinib Industry Drivers Table 12. Gefitinib Industry Opportunities and Challenges Table 13. Gefitinib Industry Restraints Table 14. Global Gefitinib Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Gefitinib Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Gefitinib Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Gefitinib Revenue Market Share by Region (2021-2026) Table 18. Global Gefitinib Revenue Market Share by Region (2027-2032) Table 19. Global Gefitinib Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k pcs) Table 20. Global Gefitinib Sales by Region (2021-2026) & (k pcs) Table 21. Global Gefitinib Sales by Region (2027-2032) & (k pcs) Table 22. Global Gefitinib Sales Market Share by Region (2021-2026) Table 23. Global Gefitinib Sales Market Share by Region (2027-2032) Table 24. Global Gefitinib Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Gefitinib Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Gefitinib Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Gefitinib Sales Market Share by Manufacturers (2021-2026) Table 28. Global Gefitinib Sales Price (US$/pcs) of Manufacturers (2021-2026) Table 29. Global Gefitinib Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Gefitinib Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Gefitinib Manufacturers, Product Type & Application Table 32. Global Gefitinib Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Gefitinib by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Gefitinib Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Gefitinib Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Gefitinib Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Gefitinib Revenue Market Share by Type (2021-2026) Table 39. Global Gefitinib Revenue Market Share by Type (2027-2032) Table 40. Global Gefitinib Sales by Type 2021 VS 2025 VS 2032 (k pcs) Table 41. Global Gefitinib Sales by Type (2021-2026) & (k pcs) Table 42. Global Gefitinib Sales by Type (2027-2032) & (k pcs) Table 43. Global Gefitinib Sales Market Share by Type (2021-2026) Table 44. Global Gefitinib Sales Market Share by Type (2027-2032) Table 45. Global Gefitinib Price by Type (2021-2026) & (US$/pcs) Table 46. Global Gefitinib Price by Type (2027-2032) & (US$/pcs) Table 47. Global Gefitinib Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Gefitinib Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Gefitinib Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Gefitinib Revenue Market Share by Application (2021-2026) Table 51. Global Gefitinib Revenue Market Share by Application (2027-2032) Table 52. Global Gefitinib Sales by Application 2021 VS 2025 VS 2032 (k pcs) Table 53. Global Gefitinib Sales by Application (2021-2026) & (k pcs) Table 54. Global Gefitinib Sales by Application (2027-2032) & (k pcs) Table 55. Global Gefitinib Sales Market Share by Application (2021-2026) Table 56. Global Gefitinib Sales Market Share by Application (2027-2032) Table 57. Global Gefitinib Price by Application (2021-2026) & (US$/pcs) Table 58. Global Gefitinib Price by Application (2027-2032) & (US$/pcs) Table 59. Qilu Pharmaceutical Company Information Table 60. Qilu Pharmaceutical Business Overview Table 61. Qilu Pharmaceutical Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 62. Qilu Pharmaceutical Gefitinib Product Portfolio Table 63. Qilu Pharmaceutical Recent Development Table 64. AstraZeneca Company Information Table 65. AstraZeneca Business Overview Table 66. AstraZeneca Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 67. AstraZeneca Gefitinib Product Portfolio Table 68. AstraZeneca Recent Development Table 69. Zuventus Healthcare Company Information Table 70. Zuventus Healthcare Business Overview Table 71. Zuventus Healthcare Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 72. Zuventus Healthcare Gefitinib Product Portfolio Table 73. Zuventus Healthcare Recent Development Table 74. United Biotech Company Information Table 75. United Biotech Business Overview Table 76. United Biotech Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 77. United Biotech Gefitinib Product Portfolio Table 78. United Biotech Recent Development Table 79. Sichuan Xieli Pharmaceutical Company Information Table 80. Sichuan Xieli Pharmaceutical Business Overview Table 81. Sichuan Xieli Pharmaceutical Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 82. Sichuan Xieli Pharmaceutical Gefitinib Product Portfolio Table 83. Sichuan Xieli Pharmaceutical Recent Development Table 84. Panacea Biotec Company Information Table 85. Panacea Biotec Business Overview Table 86. Panacea Biotec Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 87. Panacea Biotec Gefitinib Product Portfolio Table 88. Panacea Biotec Recent Development Table 89. Nobel Ilac Sanayii Ve Ticaret Company Information Table 90. Nobel Ilac Sanayii Ve Ticaret Business Overview Table 91. Nobel Ilac Sanayii Ve Ticaret Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 92. Nobel Ilac Sanayii Ve Ticaret Gefitinib Product Portfolio Table 93. Nobel Ilac Sanayii Ve Ticaret Recent Development Table 94. Nishchay Pharmaceuticals Company Information Table 95. Nishchay Pharmaceuticals Business Overview Table 96. Nishchay Pharmaceuticals Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 97. Nishchay Pharmaceuticals Gefitinib Product Portfolio Table 98. Nishchay Pharmaceuticals Recent Development Table 99. Natco Pharma Company Information Table 100. Natco Pharma Business Overview Table 101. Natco Pharma Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 102. Natco Pharma Gefitinib Product Portfolio Table 103. Natco Pharma Recent Development Table 104. Jodas Expoim Company Information Table 105. Jodas Expoim Business Overview Table 106. Jodas Expoim Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 107. Jodas Expoim Gefitinib Product Portfolio Table 108. Jodas Expoim Recent Development Table 109. Hetero Drugs Company Information Table 110. Hetero Drugs Business Overview Table 111. Hetero Drugs Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 112. Hetero Drugs Gefitinib Product Portfolio Table 113. Hetero Drugs Recent Development Table 114. Globela Pharma Company Information Table 115. Globela Pharma Business Overview Table 116. Globela Pharma Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 117. Globela Pharma Gefitinib Product Portfolio Table 118. Globela Pharma Recent Development Table 119. Glenmark Pharmaceuticals Company Information Table 120. Glenmark Pharmaceuticals Business Overview Table 121. Glenmark Pharmaceuticals Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 122. Glenmark Pharmaceuticals Gefitinib Product Portfolio Table 123. Glenmark Pharmaceuticals Recent Development Table 124. Flagship Biotech International Company Information Table 125. Flagship Biotech International Business Overview Table 126. Flagship Biotech International Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 127. Flagship Biotech International Gefitinib Product Portfolio Table 128. Flagship Biotech International Recent Development Table 129. Ethypharm Company Information Table 130. Ethypharm Business Overview Table 131. Ethypharm Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 132. Ethypharm Gefitinib Product Portfolio Table 133. Ethypharm Recent Development Table 134. Dr Reddy's Laboratories Company Information Table 135. Dr Reddy's Laboratories Business Overview Table 136. Dr Reddy's Laboratories Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 137. Dr Reddy's Laboratories Gefitinib Product Portfolio Table 138. Dr Reddy's Laboratories Recent Development Table 139. Cipla Company Information Table 140. Cipla Business Overview Table 141. Cipla Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 142. Cipla Gefitinib Product Portfolio Table 143. Cipla Recent Development Table 144. Celon Laboratories Company Information Table 145. Celon Laboratories Business Overview Table 146. Celon Laboratories Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 147. Celon Laboratories Gefitinib Product Portfolio Table 148. Celon Laboratories Recent Development Table 149. Cadila Pharmaceuticals Company Information Table 150. Cadila Pharmaceuticals Business Overview Table 151. Cadila Pharmaceuticals Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 152. Cadila Pharmaceuticals Gefitinib Product Portfolio Table 153. Cadila Pharmaceuticals Recent Development Table 154. Accure Labs Company Information Table 155. Accure Labs Business Overview Table 156. Accure Labs Gefitinib Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 157. Accure Labs Gefitinib Product Portfolio Table 158. Accure Labs Recent Development Table 159. North America Gefitinib Revenue by Type (2021-2026) & (US$ Million) Table 160. North America Gefitinib Revenue by Type (2027-2032) & (US$ Million) Table 161. North America Gefitinib Sales by Type (2021-2026) & (k pcs) Table 162. North America Gefitinib Sales by Type (2027-2032) & (k pcs) Table 163. North America Gefitinib Sales Price by Type (2021-2026) & (US$/pcs) Table 164. North America Gefitinib Sales Price by Type (2027-2032) & (US$/pcs) Table 165. North America Gefitinib Revenue by Application (2021-2026) & (US$ Million) Table 166. North America Gefitinib Revenue by Application (2027-2032) & (US$ Million) Table 167. North America Gefitinib Sales by Application (2021-2026) & (k pcs) Table 168. North America Gefitinib Sales by Application (2027-2032) & (k pcs) Table 169. North America Gefitinib Sales Price by Application (2021-2026) & (US$/pcs) Table 170. North America Gefitinib Sales Price by Application (2027-2032) & (US$/pcs) Table 171. North America Gefitinib Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 172. North America Gefitinib Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 173. North America Gefitinib Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 174. North America Gefitinib Sales by Country (2021 VS 2025 VS 2032) & (k pcs) Table 175. North America Gefitinib Sales by Country (2021-2026) & (k pcs) Table 176. North America Gefitinib Sales by Country (2027-2032) & (k pcs) Table 177. North America Gefitinib Sales Price by Country (2021-2026) & (US$/pcs) Table 178. North America Gefitinib Sales Price by Country (2027-2032) & (US$/pcs) Table 179. United States Gefitinib Revenue (2021-2032) & (US$ Million) Table 180. Canada Gefitinib Revenue (2021-2032) & (US$ Million) Table 181. Mexico Gefitinib Revenue (2021-2032) & (US$ Million) Table 182. Europe Gefitinib Revenue by Type (2021-2026) & (US$ Million) Table 183. Europe Gefitinib Revenue by Type (2027-2032) & (US$ Million) Table 184. Europe Gefitinib Sales by Type (2021-2026) & (k pcs) Table 185. Europe Gefitinib Sales by Type (2027-2032) & (k pcs) Table 186. Europe Gefitinib Sales Price by Type (2021-2026) & (US$/pcs) Table 187. Europe Gefitinib Sales Price by Type (2027-2032) & (US$/pcs) Table 188. Europe Gefitinib Revenue by Application (2021-2026) & (US$ Million) Table 189. Europe Gefitinib Revenue by Application (2027-2032) & (US$ Million) Table 190. Europe Gefitinib Sales by Application (2021-2026) & (k pcs) Table 191. Europe Gefitinib Sales by Application (2027-2032) & (k pcs) Table 192. Europe Gefitinib Sales Price by Application (2021-2026) & (US$/pcs) Table 193. Europe Gefitinib Sales Price by Application (2027-2032) & (US$/pcs) Table 194. Europe Gefitinib Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 195. Europe Gefitinib Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 196. Europe Gefitinib Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 197. Europe Gefitinib Sales by Country (2021 VS 2025 VS 2032) & (k pcs) Table 198. Europe Gefitinib Sales by Country (2021-2026) & (k pcs) Table 199. Europe Gefitinib Sales by Country (2027-2032) & (k pcs) Table 200. Europe Gefitinib Sales Price by Country (2021-2026) & (US$/pcs) Table 201. Europe Gefitinib Sales Price by Country (2027-2032) & (US$/pcs) Table 202. Germany Gefitinib Revenue (2021-2032) & (US$ Million) Table 203. France Gefitinib Revenue (2021-2032) & (US$ Million) Table 204. U.K. Gefitinib Revenue (2021-2032) & (US$ Million) Table 205. Italy Gefitinib Revenue (2021-2032) & (US$ Million) Table 206. Russia Gefitinib Revenue (2021-2032) & (US$ Million) Table 207. Spain Gefitinib Revenue (2021-2032) & (US$ Million) Table 208. Netherlands Gefitinib Revenue (2021-2032) & (US$ Million) Table 209. Switzerland Gefitinib Revenue (2021-2032) & (US$ Million) Table 210. Sweden Gefitinib Revenue (2021-2032) & (US$ Million) Table 211. Poland Gefitinib Revenue (2021-2032) & (US$ Million) Table 212. China Gefitinib Revenue by Type (2021-2026) & (US$ Million) Table 213. China Gefitinib Revenue by Type (2027-2032) & (US$ Million) Table 214. China Gefitinib Sales by Type (2021-2026) & (k pcs) Table 215. China Gefitinib Sales by Type (2027-2032) & (k pcs) Table 216. China Gefitinib Sales Price by Type (2021-2026) & (US$/pcs) Table 217. China Gefitinib Sales Price by Type (2027-2032) & (US$/pcs) Table 218. China Gefitinib Revenue by Application (2021-2026) & (US$ Million) Table 219. China Gefitinib Revenue by Application (2027-2032) & (US$ Million) Table 220. China Gefitinib Sales by Application (2021-2026) & (k pcs) Table 221. China Gefitinib Sales by Application (2027-2032) & (k pcs) Table 222. China Gefitinib Sales Price by Application (2021-2026) & (US$/pcs) Table 223. China Gefitinib Sales Price by Application (2027-2032) & (US$/pcs) Table 224. Asia Gefitinib Revenue by Type (2021-2026) & (US$ Million) Table 225. Asia Gefitinib Revenue by Type (2027-2032) & (US$ Million) Table 226. Asia Gefitinib Sales by Type (2021-2026) & (k pcs) Table 227. Asia Gefitinib Sales by Type (2027-2032) & (k pcs) Table 228. Asia Gefitinib Sales Price by Type (2021-2026) & (US$/pcs) Table 229. Asia Gefitinib Sales Price by Type (2027-2032) & (US$/pcs) Table 230. Asia Gefitinib Revenue by Application (2021-2026) & (US$ Million) Table 231. Asia Gefitinib Revenue by Application (2027-2032) & (US$ Million) Table 232. Asia Gefitinib Sales by Application (2021-2026) & (k pcs) Table 233. Asia Gefitinib Sales by Application (2027-2032) & (k pcs) Table 234. Asia Gefitinib Sales Price by Application (2021-2026) & (US$/pcs) Table 235. Asia Gefitinib Sales Price by Application (2027-2032) & (US$/pcs) Table 236. Asia Gefitinib Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 237. Asia Gefitinib Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 238. Asia Gefitinib Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 239. Asia Gefitinib Sales by Country (2021 VS 2025 VS 2032) & (k pcs) Table 240. Asia Gefitinib Sales by Country (2021-2026) & (k pcs) Table 241. Asia Gefitinib Sales by Country (2027-2032) & (k pcs) Table 242. Asia Gefitinib Sales Price by Country (2021-2026) & (US$/pcs) Table 243. Asia Gefitinib Sales Price by Country (2027-2032) & (US$/pcs) Table 244. Japan Gefitinib Revenue (2021-2032) & (US$ Million) Table 245. South Korea Gefitinib Revenue (2021-2032) & (US$ Million) Table 246. India Gefitinib Revenue (2021-2032) & (US$ Million) Table 247. Australia Gefitinib Revenue (2021-2032) & (US$ Million) Table 248. Taiwan Gefitinib Revenue (2021-2032) & (US$ Million) Table 249. Southeast Asia Gefitinib Revenue (2021-2032) & (US$ Million) Table 250. SAMEA Gefitinib Revenue by Type (2021-2026) & (US$ Million) Table 251. SAMEA Gefitinib Revenue by Type (2027-2032) & (US$ Million) Table 252. SAMEA Gefitinib Sales by Type (2021-2026) & (k pcs) Table 253. SAMEA Gefitinib Sales by Type (2027-2032) & (k pcs) Table 254. SAMEA Gefitinib Sales Price by Type (2021-2026) & (US$/pcs) Table 255. SAMEA Gefitinib Sales Price by Type (2027-2032) & (US$/pcs) Table 256. SAMEA Gefitinib Revenue by Application (2021-2026) & (US$ Million) Table 257. SAMEA Gefitinib Revenue by Application (2027-2032) & (US$ Million) Table 258. SAMEA Gefitinib Sales by Application (2021-2026) & (k pcs) Table 259. SAMEA Gefitinib Sales by Application (2027-2032) & (k pcs) Table 260. SAMEA Gefitinib Sales Price by Application (2021-2026) & (US$/pcs) Table 261. SAMEA Gefitinib Sales Price by Application (2027-2032) & (US$/pcs) Table 262. SAMEA Gefitinib Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 263. SAMEA Gefitinib Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 264. SAMEA Gefitinib Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 265. SAMEA Gefitinib Sales by Country (2021 VS 2025 VS 2032) & (k pcs) Table 266. SAMEA Gefitinib Sales by Country (2021-2026) & (k pcs) Table 267. SAMEA Gefitinib Sales by Country (2027-2032) & (k pcs) Table 268. SAMEA Gefitinib Sales Price by Country (2021-2026) & (US$/pcs) Table 269. SAMEA Gefitinib Sales Price by Country (2027-2032) & (US$/pcs) Table 270. Brazil Gefitinib Revenue (2021-2032) & (US$ Million) Table 271. Argentina Gefitinib Revenue (2021-2032) & (US$ Million) Table 272. Chile Gefitinib Revenue (2021-2032) & (US$ Million) Table 273. Colombia Gefitinib Revenue (2021-2032) & (US$ Million) Table 274. Peru Gefitinib Revenue (2021-2032) & (US$ Million) Table 275. Saudi Arabia Gefitinib Revenue (2021-2032) & (US$ Million) Table 276. Israel Gefitinib Revenue (2021-2032) & (US$ Million) Table 277. UAE Gefitinib Revenue (2021-2032) & (US$ Million) Table 278. Turkey Gefitinib Revenue (2021-2032) & (US$ Million) Table 279. Iran Gefitinib Revenue (2021-2032) & (US$ Million) Table 280. Egypt Gefitinib Revenue (2021-2032) & (US$ Million) Table 281. Key Raw Materials Table 282. Raw Materials Key Suppliers Table 283. Gefitinib Distributors List Table 284. Gefitinib Customers List Table 285. Research Programs/Design for This Report Table 286. Authors List of This Report Table 287. Secondary Sources Table 288. Primary Sources List of Figures Figure 1. Gefitinib Image Figure 2. Global Gefitinib Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gefitinib Market Size Share 2021 VS 2025 VS 2032 Figure 4. 10 Tables/Box Image Figure 5. 30 Tables/Box Image Figure 6. 90 Tables/Box Image Figure 7. Global Gefitinib Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Gefitinib Market Size Share 2021 VS 2025 VS 2032 Figure 9. Drug Center Image Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Others Image Figure 13. Global Gefitinib Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Gefitinib Revenue (2021-2032) & (US$ Million) Figure 15. Global Gefitinib Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Gefitinib Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Gefitinib Revenue Market Share by Region (2021-2032) Figure 18. Global Gefitinib Sales (2021-2032) & (k pcs) Figure 19. Global Gefitinib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Figure 20. Global Gefitinib Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Gefitinib Sales YoY (2021-2032) & (k pcs) Figure 22. Europe Gefitinib Sales YoY (2021-2032) & (k pcs) Figure 23. China Gefitinib Sales YoY (2021-2032) & (k pcs) Figure 24. Asia (Excluding China) Gefitinib Sales YoY (2021-2032) & (k pcs) Figure 25. South America, Middle East and Africa Gefitinib Sales YoY (2021-2032) & (k pcs) Figure 26. Global Gefitinib Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Gefitinib Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Gefitinib Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Gefitinib Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Gefitinib Revenue Market Share by Type (2021-2032) Figure 32. Global Gefitinib Sales by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 33. Global Gefitinib Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Gefitinib Sales Market Share by Type (2021-2032) Figure 35. Global Gefitinib Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Gefitinib Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Gefitinib Revenue Market Share by Application (2021-2032) Figure 38. Global Gefitinib Sales by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 39. Global Gefitinib Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Gefitinib Sales Market Share by Application (2021-2032) Figure 41. North America Gefitinib Revenue Share by Type (2021-2032) Figure 42. North America Gefitinib Sales Share by Type (2021-2032) Figure 43. North America Gefitinib Revenue Share by Application (2021-2032) Figure 44. North America Gefitinib Sales Share by Application (2021-2032) Figure 45. North America Gefitinib Revenue Share by Country (2021-2032) Figure 46. North America Gefitinib Sales Share by Country (2021-2032) Figure 47. Europe Gefitinib Revenue Share by Type (2021-2032) Figure 48. Europe Gefitinib Sales Share by Type (2021-2032) Figure 49. Europe Gefitinib Revenue Share by Application (2021-2032) Figure 50. Europe Gefitinib Sales Share by Application (2021-2032) Figure 51. Europe Gefitinib Revenue Share by Country (2021-2032) Figure 52. Europe Gefitinib Sales Share by Country (2021-2032) Figure 53. China Gefitinib Revenue Share by Type (2021-2032) Figure 54. China Gefitinib Sales Share by Type (2021-2032) Figure 55. China Gefitinib Revenue Share by Application (2021-2032) Figure 56. China Gefitinib Sales Share by Application (2021-2032) Figure 57. Asia Gefitinib Revenue Share by Type (2021-2032) Figure 58. Asia Gefitinib Sales Share by Type (2021-2032) Figure 59. Asia Gefitinib Revenue Share by Application (2021-2032) Figure 60. Asia Gefitinib Sales Share by Application (2021-2032) Figure 61. Asia Gefitinib Revenue Share by Country (2021-2032) Figure 62. Asia Gefitinib Sales Share by Country (2021-2032) Figure 63. SAMEA Gefitinib Revenue Share by Type (2021-2032) Figure 64. SAMEA Gefitinib Sales Share by Type (2021-2032) Figure 65. SAMEA Gefitinib Revenue Share by Application (2021-2032) Figure 66. SAMEA Gefitinib Sales Share by Application (2021-2032) Figure 67. SAMEA Gefitinib Revenue Share by Country (2021-2032) Figure 68. SAMEA Gefitinib Sales Share by Country (2021-2032) Figure 69. Gefitinib Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Gefitinib Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • 10 Tables/Box
  • 30 Tables/Box
  • 90 Tables/Box
Applications
  • Drug Center
  • Hospital
  • Clinic
  • Others
Companies covered
  • Qilu Pharmaceutical
  • AstraZeneca
  • Zuventus Healthcare
  • United Biotech
  • Sichuan Xieli Pharmaceutical
  • Panacea Biotec
  • Nobel Ilac Sanayii Ve Ticaret
  • Nishchay Pharmaceuticals
  • Natco Pharma
  • Jodas Expoim
  • Hetero Drugs
  • Globela Pharma
  • Glenmark Pharmaceuticals
  • Flagship Biotech International
  • Ethypharm
  • Dr Reddy's Laboratories
  • Cipla
  • Celon Laboratories
  • Cadila Pharmaceuticals
  • Accure Labs

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Gefitinib Market by Type
  3. 1.2.1 Global Gefitinib Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 10 Tables/Box
  5. 1.2.3 30 Tables/Box
  6. 1.2.4 90 Tables/Box
  7. 1.3 Gefitinib Market by Application
  8. 1.3.1 Global Gefitinib Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Drug Center
  10. 1.3.3 Hospital
  11. 1.3.4 Clinic
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Gefitinib Market Dynamics
  1. 2.1 Gefitinib Industry Trends
  2. 2.2 Gefitinib Industry Drivers
  3. 2.3 Gefitinib Industry Opportunities and Challenges
  4. 2.4 Gefitinib Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Gefitinib Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Gefitinib Revenue by Region
  3. 3.2.1 Global Gefitinib Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Gefitinib Revenue by Region (2021-2026)
  5. 3.2.3 Global Gefitinib Revenue by Region (2027-2032)
  6. 3.2.4 Global Gefitinib Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Gefitinib Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Gefitinib Sales by Region
  9. 3.4.1 Global Gefitinib Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Gefitinib Sales by Region (2021-2026)
  11. 3.4.3 Global Gefitinib Sales by Region (2027-2032)
  12. 3.4.4 Global Gefitinib Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Gefitinib Revenue by Manufacturers
  2. 4.1.1 Global Gefitinib Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Gefitinib Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Gefitinib Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Gefitinib Sales by Manufacturers
  6. 4.2.1 Global Gefitinib Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Gefitinib Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Gefitinib Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Gefitinib Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Gefitinib Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Gefitinib Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Gefitinib Manufacturers, Product Type & Application
  13. 4.7 Global Gefitinib Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Gefitinib Market CR5 and HHI
  16. 4.8.2 2025 Gefitinib Tier 1, Tier 2, and Tier 3
5 Gefitinib Market by Type
  1. 5.1 Global Gefitinib Revenue by Type
  2. 5.1.1 Global Gefitinib Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Gefitinib Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Gefitinib Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Gefitinib Sales by Type
  6. 5.2.1 Global Gefitinib Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Gefitinib Sales by Type (2021-2032) & (k pcs)
  8. 5.2.3 Global Gefitinib Sales Market Share by Type (2021-2032)
  9. 5.3 Global Gefitinib Price by Type
6 Gefitinib Market by Application
  1. 6.1 Global Gefitinib Revenue by Application
  2. 6.1.1 Global Gefitinib Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Gefitinib Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Gefitinib Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Gefitinib Sales by Application
  6. 6.2.1 Global Gefitinib Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Gefitinib Sales by Application (2021-2032) & (k pcs)
  8. 6.2.3 Global Gefitinib Sales Market Share by Application (2021-2032)
  9. 6.3 Global Gefitinib Price by Application
7 Company Profiles
  1. 7.1 Qilu Pharmaceutical
  2. 7.1.1 Qilu Pharmaceutical Company Information
  3. 7.1.2 Qilu Pharmaceutical Business Overview
  4. 7.1.3 Qilu Pharmaceutical Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Qilu Pharmaceutical Gefitinib Product Portfolio
  6. 7.1.5 Qilu Pharmaceutical Recent Developments
  7. 7.2 AstraZeneca
  8. 7.2.1 AstraZeneca Company Information
  9. 7.2.2 AstraZeneca Business Overview
  10. 7.2.3 AstraZeneca Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 AstraZeneca Gefitinib Product Portfolio
  12. 7.2.5 AstraZeneca Recent Developments
  13. 7.3 Zuventus Healthcare
  14. 7.3.1 Zuventus Healthcare Company Information
  15. 7.3.2 Zuventus Healthcare Business Overview
  16. 7.3.3 Zuventus Healthcare Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Zuventus Healthcare Gefitinib Product Portfolio
  18. 7.3.5 Zuventus Healthcare Recent Developments
  19. 7.4 United Biotech
  20. 7.4.1 United Biotech Company Information
  21. 7.4.2 United Biotech Business Overview
  22. 7.4.3 United Biotech Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 United Biotech Gefitinib Product Portfolio
  24. 7.4.5 United Biotech Recent Developments
  25. 7.5 Sichuan Xieli Pharmaceutical
  26. 7.5.1 Sichuan Xieli Pharmaceutical Company Information
  27. 7.5.2 Sichuan Xieli Pharmaceutical Business Overview
  28. 7.5.3 Sichuan Xieli Pharmaceutical Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Sichuan Xieli Pharmaceutical Gefitinib Product Portfolio
  30. 7.5.5 Sichuan Xieli Pharmaceutical Recent Developments
  31. 7.6 Panacea Biotec
  32. 7.6.1 Panacea Biotec Company Information
  33. 7.6.2 Panacea Biotec Business Overview
  34. 7.6.3 Panacea Biotec Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Panacea Biotec Gefitinib Product Portfolio
  36. 7.6.5 Panacea Biotec Recent Developments
  37. 7.7 Nobel Ilac Sanayii Ve Ticaret
  38. 7.7.1 Nobel Ilac Sanayii Ve Ticaret Company Information
  39. 7.7.2 Nobel Ilac Sanayii Ve Ticaret Business Overview
  40. 7.7.3 Nobel Ilac Sanayii Ve Ticaret Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Nobel Ilac Sanayii Ve Ticaret Gefitinib Product Portfolio
  42. 7.7.5 Nobel Ilac Sanayii Ve Ticaret Recent Developments
  43. 7.8 Nishchay Pharmaceuticals
  44. 7.8.1 Nishchay Pharmaceuticals Company Information
  45. 7.8.2 Nishchay Pharmaceuticals Business Overview
  46. 7.8.3 Nishchay Pharmaceuticals Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Nishchay Pharmaceuticals Gefitinib Product Portfolio
  48. 7.8.5 Nishchay Pharmaceuticals Recent Developments
  49. 7.9 Natco Pharma
  50. 7.9.1 Natco Pharma Company Information
  51. 7.9.2 Natco Pharma Business Overview
  52. 7.9.3 Natco Pharma Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Natco Pharma Gefitinib Product Portfolio
  54. 7.9.5 Natco Pharma Recent Developments
  55. 7.10 Jodas Expoim
  56. 7.10.1 Jodas Expoim Company Information
  57. 7.10.2 Jodas Expoim Business Overview
  58. 7.10.3 Jodas Expoim Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Jodas Expoim Gefitinib Product Portfolio
  60. 7.10.5 Jodas Expoim Recent Developments
  61. 7.11 Hetero Drugs
  62. 7.11.1 Hetero Drugs Company Information
  63. 7.11.2 Hetero Drugs Business Overview
  64. 7.11.3 Hetero Drugs Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Hetero Drugs Gefitinib Product Portfolio
  66. 7.11.5 Hetero Drugs Recent Developments
  67. 7.12 Globela Pharma
  68. 7.12.1 Globela Pharma Company Information
  69. 7.12.2 Globela Pharma Business Overview
  70. 7.12.3 Globela Pharma Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Globela Pharma Gefitinib Product Portfolio
  72. 7.12.5 Globela Pharma Recent Developments
  73. 7.13 Glenmark Pharmaceuticals
  74. 7.13.1 Glenmark Pharmaceuticals Company Information
  75. 7.13.2 Glenmark Pharmaceuticals Business Overview
  76. 7.13.3 Glenmark Pharmaceuticals Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Glenmark Pharmaceuticals Gefitinib Product Portfolio
  78. 7.13.5 Glenmark Pharmaceuticals Recent Developments
  79. 7.14 Flagship Biotech International
  80. 7.14.1 Flagship Biotech International Company Information
  81. 7.14.2 Flagship Biotech International Business Overview
  82. 7.14.3 Flagship Biotech International Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Flagship Biotech International Gefitinib Product Portfolio
  84. 7.14.5 Flagship Biotech International Recent Developments
  85. 7.15 Ethypharm
  86. 7.15.1 Ethypharm Company Information
  87. 7.15.2 Ethypharm Business Overview
  88. 7.15.3 Ethypharm Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Ethypharm Gefitinib Product Portfolio
  90. 7.15.5 Ethypharm Recent Developments
  91. 7.16 Dr Reddy's Laboratories
  92. 7.16.1 Dr Reddy's Laboratories Company Information
  93. 7.16.2 Dr Reddy's Laboratories Business Overview
  94. 7.16.3 Dr Reddy's Laboratories Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Dr Reddy's Laboratories Gefitinib Product Portfolio
  96. 7.16.5 Dr Reddy's Laboratories Recent Developments
  97. 7.17 Cipla
  98. 7.17.1 Cipla Company Information
  99. 7.17.2 Cipla Business Overview
  100. 7.17.3 Cipla Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Cipla Gefitinib Product Portfolio
  102. 7.17.5 Cipla Recent Developments
  103. 7.18 Celon Laboratories
  104. 7.18.1 Celon Laboratories Company Information
  105. 7.18.2 Celon Laboratories Business Overview
  106. 7.18.3 Celon Laboratories Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Celon Laboratories Gefitinib Product Portfolio
  108. 7.18.5 Celon Laboratories Recent Developments
  109. 7.19 Cadila Pharmaceuticals
  110. 7.19.1 Cadila Pharmaceuticals Company Information
  111. 7.19.2 Cadila Pharmaceuticals Business Overview
  112. 7.19.3 Cadila Pharmaceuticals Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Cadila Pharmaceuticals Gefitinib Product Portfolio
  114. 7.19.5 Cadila Pharmaceuticals Recent Developments
  115. 7.20 Accure Labs
  116. 7.20.1 Accure Labs Company Information
  117. 7.20.2 Accure Labs Business Overview
  118. 7.20.3 Accure Labs Gefitinib Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Accure Labs Gefitinib Product Portfolio
  120. 7.20.5 Accure Labs Recent Developments
8 North America
  1. 8.1 North America Gefitinib Market Size by Type
  2. 8.1.1 North America Gefitinib Revenue by Type (2021-2032)
  3. 8.1.2 North America Gefitinib Sales by Type (2021-2032)
  4. 8.1.3 North America Gefitinib Price by Type (2021-2032)
  5. 8.2 North America Gefitinib Market Size by Application
  6. 8.2.1 North America Gefitinib Revenue by Application (2021-2032)
  7. 8.2.2 North America Gefitinib Sales by Application (2021-2032)
  8. 8.2.3 North America Gefitinib Price by Application (2021-2032)
  9. 8.3 North America Gefitinib Market Size by Country
  10. 8.3.1 North America Gefitinib Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Gefitinib Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Gefitinib Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Gefitinib Market Size by Type
  2. 9.1.1 Europe Gefitinib Revenue by Type (2021-2032)
  3. 9.1.2 Europe Gefitinib Sales by Type (2021-2032)
  4. 9.1.3 Europe Gefitinib Price by Type (2021-2032)
  5. 9.2 Europe Gefitinib Market Size by Application
  6. 9.2.1 Europe Gefitinib Revenue by Application (2021-2032)
  7. 9.2.2 Europe Gefitinib Sales by Application (2021-2032)
  8. 9.2.3 Europe Gefitinib Price by Application (2021-2032)
  9. 9.3 Europe Gefitinib Market Size by Country
  10. 9.3.1 Europe Gefitinib Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Gefitinib Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Gefitinib Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Gefitinib Market Size by Type
  2. 10.1.1 China Gefitinib Revenue by Type (2021-2032)
  3. 10.1.2 China Gefitinib Sales by Type (2021-2032)
  4. 10.1.3 China Gefitinib Price by Type (2021-2032)
  5. 10.2 China Gefitinib Market Size by Application
  6. 10.2.1 China Gefitinib Revenue by Application (2021-2032)
  7. 10.2.2 China Gefitinib Sales by Application (2021-2032)
  8. 10.2.3 China Gefitinib Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Gefitinib Market Size by Type
  2. 11.1.1 Asia Gefitinib Revenue by Type (2021-2032)
  3. 11.1.2 Asia Gefitinib Sales by Type (2021-2032)
  4. 11.1.3 Asia Gefitinib Price by Type (2021-2032)
  5. 11.2 Asia Gefitinib Market Size by Application
  6. 11.2.1 Asia Gefitinib Revenue by Application (2021-2032)
  7. 11.2.2 Asia Gefitinib Sales by Application (2021-2032)
  8. 11.2.3 Asia Gefitinib Price by Application (2021-2032)
  9. 11.3 Asia Gefitinib Market Size by Country
  10. 11.3.1 Asia Gefitinib Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Gefitinib Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Gefitinib Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Gefitinib Market Size by Type
  2. 12.1.1 SAMEA Gefitinib Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Gefitinib Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Gefitinib Price by Type (2021-2032)
  5. 12.2 SAMEA Gefitinib Market Size by Application
  6. 12.2.1 SAMEA Gefitinib Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Gefitinib Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Gefitinib Price by Application (2021-2032)
  9. 12.3 SAMEA Gefitinib Market Size by Country
  10. 12.3.1 SAMEA Gefitinib Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Gefitinib Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Gefitinib Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Gefitinib Value Chain Analysis
  2. 13.1.1 Gefitinib Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Gefitinib Production Mode & Process
  6. 13.2 Gefitinib Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Gefitinib Distributors
  9. 13.2.3 Gefitinib Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst